泌尿器系悪性腫瘍に対するZ4942(Ifosfamide)の臨床評価

Abstract

A joint clinical research was made by twelve institutions on evaluation of Z4942 (Ifosfamide) for malignant urological tumors. The following results were obtained. 1) Eighty terminal cases refractory to the previous treatments were treated with Ifosfamide administered 2 to 3 grams per day for 3 to 5 days as one course. The patients received 2.5 courses in average. Ten (29.4%) out of 34 evaluable patients treated only with Ifosfamide and 21 (63.6%) of 33 patients receiving it in a combination chemotherapy showed the response of 1-A or better on Karnofsky performance scale. 2) Malignancies which responded were testicular tumor (5/13, 38.5%) and prostatic cancer (4/9, 44.4%) in the sole administration group whereas testicular tumor (5/7, 71.4%), prostatic cancer (6/7, 85.7%), bladder cancer (5/9, 55.6%), penile cancer, transitional epithelial cancer of the prostate, sarcoma of the bladder and sarcoma of the prostate in the combination therapy group. 3) Leucopenia, vomiting, depilation and general malaise were noted in a little more than half of the cases. Other untoward reactions observed were erythrocytopenia, thrombocytopenia, high BUN, high GOT, high GPT, nausea, anorexia, diarrhea, chill, fever, CNS disturbance and headache. They were, however, transient and few cases required to discontinue the medication. From the results mentioned above, it was concluded that Ifosfamide can be expected as one of the weapons against urologic malignancies.